Results 121 to 130 of about 103,766,681 (205)

HIV-2 evades restriction by ZAP through adaptations in the U3 LTR region despite increased CpG levels. [PDF]

Nucleic Acids Res
Kmiec D, Nchioua R, Gabel A, Vlachou A, Ganskih S, Erdemci-Evin S, A Lapp S, G Carnathan D, E Bosinger S, Berkhout B, T Das A, Munschauer M, Kirchhoff F.   +12 more
europepmc   +1 more source

Mycobacterium tuberculosis PE_PGRS62 Protein Inhibits Type I Interferon Responses to Promote HIV-2 Replication by Directly Interacting With Interferon Regulatory Factor 3. [PDF]

J Infect Dis
Pan C, Xu H, Huang M, He J, Li S, Tao X, Cao T, Zhang G.   +7 more
europepmc   +1 more source

PHD3-VHL axis controls HIV-2 infection through oxygen-dependent hydroxylation and degradation of Vpx. [PDF]

PLoS Pathog
Miyakawa K, Tanaka K, Ino Y, Kimura Y, Kameya T, Mizukoshi F, Nishi M, Yokoyama M, Nakabayashi J, Nomaguchi M, Sato H, Kimura H, Akari H, Miura T, Takaoka A, Hasegawa H, Matano T, Minamishima YA, Ryo A.   +18 more
europepmc   +1 more source

Macrophage-Derived Factors with the Potential to Contribute to the Pathogenicity of HIV-1 and HIV-2: Roles of M-CSF and CXCL7. [PDF]

Int J Mol Sci
Gao C, Kutza J, Ouyang W, Grimm TA, Fields K, Lankford CSR, Schwartzkopff F, Paciga M, Machuca A, Tiffany L, Stantchev T, Clouse KA.   +11 more
europepmc   +1 more source

Estimating the Economic Consequences of Leveraging the Novel cobas HIV-1/HIV-2 Qualitative Nucleic Acid Amplification Test in Routine HIV Testing. [PDF]

Clin Infect Dis
Bilir SP, Krishnamurthy P, Karichu JK, Blosser SJ, Hernandez D, Tchelidze T, Tawiah K, Ferrufino CP.   +7 more
europepmc   +1 more source

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. [PDF]

J Infect Dis
Smith RA, Raugi DN, Nixon RS, Seydi M, Margot NA, Callebaut C, Gottlieb GS, University of Washington–Senegal HIV-2 Study Group.   +7 more
europepmc   +1 more source

Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients. [PDF]

PLoS One
Koffi JJ, Boni SP, Mba L, Bitty-Anderson A, Tchabert AG, Toure FY, Coffie PA, Inwoley A, Eholie SP, Ekouevi DK, Tchounga B.   +10 more
europepmc   +1 more source

Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1. [PDF]

J Virol
Cui W, Wang H, Gao Y, Zhang X, Xin J, Li Z, Li G, Gao W, Zhang W.   +8 more
europepmc   +1 more source

Structural insights into HIV-2 CA lattice formation and FG-pocket binding revealed by single-particle cryo-EM. [PDF]

Cell Rep
Cook M, Freniere C, Wu C, Lozano F, Xiong Y.   +4 more
europepmc   +1 more source

Prevalence of HIV-2 infection in Mumbai

Indian Journal of Dermatology, Venereology, and Leprology, 2010
Agrawal, Sachee, Sawant, Sandhya, Shastri, Jayanthi   +2 more
openaire   +2 more sources